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ABSTRACT 
Background: Identifying asthma patients suitable for biologic therapy includes the 
assessment of blood biomarkers (IgE and eosinophils (EOS)). How they relate to 
each other is unclear.  
Methods: This retrospective, database study used routinely collected clinical data to 
identify and evaluate an asthma cohort (classification code for asthma; ≥ 18 years; 
≥1 prescription for asthma; ≥1 estimation of serum IgE, in 2 years prior to index 
date). Distribution into high and low IgE and EOS groups (IgE cut-point: > or ≤75 
kU/L; EOS cut point: >or ≤400 µ/L), and characteristics by group are described. 
Findings: In patients with severe asthma (British Thoracic Society Step (BTS) ≥4; 
N=884), using maximum recorded IgE/EOS, 33% had high IgE/high EOS, 28% low 
IgE/low EOS and approximately a fifth each had high IgE/low EOS or low IgE/high 
EOS. Proportions were similar when EOS values measured 2 or 4 weeks before an 
exacerbation were excluded. Using EOS/IgE ’same day’ measurements (N=578) 
only identified half of the high EOS group. Patients in high IgE groups were more 
likely to be younger males without comorbid COPD; those in high EOS groups were 
more likely to be on BTS treatment Step 5 vs 4. The low IgE/low EOS group had the 
lowest incidence of asthma-related hospital attendances, the highest incidence was 
observed in the high EOS groups.  
Conclusion: Maximum available EOS measurement irrespective of exacerbations 
may be relevant when considering therapy.  These data showed low IgE/Low EOS to 
be more benign and high EOS groups at increased risk of frequent, severe 
exacerbations.  
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INTRODUCTION 
Whilst most patients with asthma can be effectively treated with traditional 
pharmacological therapy (inhaled corticosteroids (ICS), short or long acting 
bronchodilators and / or leukotriene receptor antagonists), a subset (<10%) with 
severe asthma are difficult to treat and account for a disproportionately large 
proportion of asthma morbidity and associated healthcare costs [1-3]. Severe asthma 
is defined as asthma that requires treatment with high dose inhaled corticosteroids 
(ICS) plus a second controller and/or systemic corticosteroids to prevent it from 
becoming ‘‘uncontrolled’’ or that remains ‘‘uncontrolled’’ despite this therapy [3]. It is 
increasingly recognized as a heterogeneous disease comprising multiple 
phenotypes, both at the clinical and molecular level [3], and further progress in 
identifying and understanding severe asthma phenotypes will enable targeted and 
personalized treatment, particularly in the field of biologic therapies. 
Predicting responders to biologic therapy requires assessment of blood biomarkers 
that may not be routinely collected or considered in clinical practice. Such therapies 
are restricted in use by both an assessment of need after optimised care and a 
biomarker profile consistent with product licenses. Two established phenotype-
targeted biologic therapies in severe asthma are those based on humanized 
monoclonal antibodies against immunoglobulin E (IgE), in severe allergic asthma, 
and interleukin-5 (IL-5), in eosinophilic asthma [4-6]. Eosinophilic asthma, associated 
with raised blood and sputum eosinophils and recurrent exacerbations, occurs in 
both allergic and non-allergic asthma patients, the pathophysiological mechanisms of 
the latter yet to be fully understood [7]. How these two biomarkers relate to each 
other is unclear.  Sub-phenotypes of asthma that will respond differently to IgE or 
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Th2 cytokine targeting have been proposed, summarised in a 2x2 matrix diagram, 
outlining four groups by their blood eosinophil and IgE status (high and low) [8]. As 
part of the current analysis, we aimed to ‘populate’ this matrix with real-world patient 
data. 
The measurement of blood eosinophils and serum IgE is available in routine clinical 
practice. By defining the biomarker status of a cohort of people with severe asthma, 
the potential impact of precision medicine through appropriate biologic therapies for 
these patients may be estimated. This analysis used a large, geographically defined, 
electronic database to describe the distribution and characteristics of patients with 
severe asthma according to their IgE and eosinophil biomarker levels. 
METHODS 
Study design and population 
This was a retrospective, cohort, database study which used routinely collected 
clinical data from the whole population of National Health Service Greater Glasgow 
and Clyde (NHSGGC), in the 2 years prior to a pre-defined index date of 1st Jan 
2016. Included patients met the following criteria: 1) Presence of a Read code [9] or 
International Classification of Diseases (ICD) code [10] for asthma (ever recorded), 
2) Aged ≥ 18 years, 3) ≥ one prescription for any of: short-acting beta2-agonist 
(SABA), inhaled corticosteroid (ICS), ICS/long-acting beta2-agonist (LABA) 
combination, 4) ≥ one estimation of serum IgE.  
Patients with a read or ICD code for hyper IgE(Job) syndrome, parasitic infection, 
allergic bronchopulmonary aspergillosis (ABPA), Churg Strauss / vasculitides, 
multiple myeloma, or autoimmune disease, were excluded. Patients with a read or 
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ICD code for bronchiectasis or interstitial lung disease, were excluded from analyses 
of exacerbations data. 
The study protocol was registered and conducted according to The European 
Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) 
((Ref:ENCEPP/SDPP/13134) code of conduct [11]. The database was generated by 
the NHSGGC Safe Haven, a large research resource which links health information 
datasets at the patient level. Data were then transferred to the University of 
Aberdeen Safe Haven for analysis.  As part of this process, patient identifiable data 
is not released to researchers, but instead datasets are linked in-house before 
releasing the full research dataset in an anonymised format. Therefore, ethics 
approval and patient informed consent were not required for this study. 
Study outcomes 
Data items collected were: age at index date, sex, height, weight, body mass index 
(BMI), smoking status, concurrent therapies for asthma (number of prescriptions), 
co-morbidities (read or ICD code), and biologic marker counts and date of 
measurement. The current therapies of interest were: SABA, LABA, long-acting 
muscarinic antagonists (LAMA), ICS, ICS/LABA, leukotriene receptor antagonists 
(LTRA), theophylline, and prednisolone <20 mg/day (indicating chronic, not acute, 
usage) in the 2 years prior to the index date. Co-morbidities of interest were: chronic 
obstructive pulmonary disease, cardiovascular disease, cerebrovascular disease, 
diabetes mellitus, depression, osteoporosis, interstitial lung disease, nasal polyposis. 
Total IgE measurements were done by Fluorescence Enzyme Immunoassay (FEIA) 
on an Immunocap250 instrument (Phadia, Sweden). Eosinophil counts were carried 
out as part of the full blood count. These were performed on Sysmex XN10 
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analysers (Sysmex UK Ltd, UK), using fluorescent laser light scatter technology. 
Consistent methodology was applied across NHSGGC. 
The number of asthma exacerbations in the two years prior to the index date were 
recorded, defined as 1) prescription of oral corticosteroids ≥ 20 mg per day for 
asthma, 2) attendance at an emergency department due to asthma, 3) 
hospitalisation due to asthma. Severe exacerbations were defined as those requiring 
a visit to an emergency department or hospitalisation due to asthma.  Every effort 
was made to identify attendances due to a primary diagnosis of asthma within the 
limits of the coding available.   
Due to lack of accessible electronic recording, spirometry data cannot currently be 
accessed through the Safe Haven database. 
Statistical analyses 
For this analysis, the population of interest were those with severe asthma, defined 
as Step 4 and above in the British Thoracic Society and Scottish Intercollegiate 
Guidelines Network (BTS/SIGN) recommendations for asthma, version current at the 
time of study conduct [12]. The following IgE and eosinophil (EOS) distribution 
groups were determined:  high EOS/high IgE, high EOS/low IgE, low EOS/high IgE, 
low EOS/low IgE, where IgE cut-point was defined as > or ≤75 kU/L; EOS cut point: 
> or ≤400 µ/L. Two analysis cohorts were considered: 1) the maximum value 
recorded for IgE and EOS in the two years prior to the index state, 2) the value of 
EOS or IgE corresponding to the same day measurement as IgE or EOS 
respectively, at any time in the two years prior to the index date. 
Summary statistics were produced for all patient characteristics and included the 
mean and standard deviation (SD) or median and range (min-max) for continuous 
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data and number (percentage) for categorical data.  Demographic and clinical factors 
were compared across IgE and eosinophil distribution groups.  The chi squared test 
was used to compare categorical factors across groups, whilst the Kruskall-Wallis 
test was used to compare the distribution of continuous variables across IgE and 
eosinophil distribution groups.     
All analyses were carried out using IBM SPSS Statistics version 23. Statistically 
significant results were defined as p≤0.05. 
RESULTS 
Patient population 
Of the 1.36 million patients on the NHSGGC database, 1507 met the inclusion 
criteria for adults with a diagnosis of asthma and presence of a serum IgE 
measurement in the two years prior to the index date, of which 884 had severe 
asthma (BTS Step ≥4) (Figure 1). Within this group, 852 patients also had a 
recorded EOS measurement, and 578 had a same day IgE and Eos measurement.  
In this severe patient population, mean (standard deviation, SD) age was 54.7 (15.9) 
years, a quarter were current smokers and approximately a third each had comorbid 
COPD and comorbid allergy (Table 1). Median (interquartile range) IgE and 
eosinophil counts were 86 (22-289) kU/L and 400 (200-700) µ/L respectively. Over 
half this group (55%) had suffered at least one asthma exacerbation in the prior two 
years, and 32% and 22% respectively had been hospitalized once or at least twice 
for asthma. Ninety-six percent of patients had been prescribed an ICS/LABA at least 
once in the prior two years; 66% had been prescribed a LTRA. 
Distribution of patients by IgE and EOS level 
8 
 
The distribution of patients by their maximum measured IgE and EOS levels in the 
prior two years is shown in Table 2 and Figure 2a. Thirty three percent of patients 
had both high IgE and EOS levels, 19% had high IgE/low EOS, 20% had low 
IgE/high EOS, and 28% had low IgE and low EOS. This distribution pattern varied 
when data for same day EOS and IgE measurements were used, with the proportion 
of patients showing high EOS levels, on this occasion, being markedly lower (Figure 
2b). The exclusion of EOS data measured 2 and 4 weeks before an exacerbation 
had no observable impact on the maximum IgE/EOS distribution groups (Figure 2c 
and 2d). 
The correlation between IgE and EOS levels, measured on the same day was weak 
(Rank correlation coefficient: 0.276) (Figure 3). 
Clinical Characteristics of patients by IgE/EOS groups 
Patients in high IgE groups were younger, more likely to be male and less likely to 
have comorbid COPD than patients in low IgE groups (Table 3). The significantly 
higher occurrence of COPD in the low IgE groups was not accompanied by 
differences in smoking status. Patients in high EOS groups were significantly more 
likely to be on BTS Step 5 than Step 4, and had increased levels of systemic 
inflammation (as measured by c-reactive protein levels) compared with those in low 
EOS groups. Compared with other distribution groups, patients with high EOS/low 
IgE were more likely to have comorbid osteoporosis, and showed the greatest levels 
of systemic inflammation.  
Asthma exacerbations and asthma therapies according to IgE/EOS groups 
Across IgE/EOS groups, there were no significant differences in the number of 
asthma exacerbations requiring oral corticosteroids in the two years prior to the 
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index date (Table 4). The proportion of frequent exacerbators, defined as those with 
≥2 prescriptions for oral corticosteroids or ≥ 1 hospital admission for asthma in the 
year prior to the index date, was significantly different across IgE/EOS groups with 
the highest frequency observed in the high IgE/high EOS group (76% vs. a range of 
60%-68% in the other groups, p<0.001). The incidence of severe frequent 
exacerbations i.e. those requiring hospitalisation or an emergency department visit, 
was also significantly different across groups with the highest frequencies observed 
in the high EOS groups (Table 4). No significant differences were observed in the 
frequencies of moderate or severe exacerbations between patients with high EOS 
(regardless of IgE status) and those with high IgE (regardless of EOS status) (data 
not shown).  
There were no significant differences across groups in prescriptions for maintenance 
therapies (Table 4).  
DISCUSSION 
This analysis describes the distribution and characteristics of patients according to 
their blood IgE and eosinophil biomarker levels, in a highly treated, severe asthma 
population. When using maximum-recorded IgE and EOS, a third of patients had 
both high IgE and EOS levels, a fifth each had high IgE/low EOS and low IgE/high 
EOS, and approximately a quarter had both low IgE and EOS levels. The distribution 
of patients was noticeably different when using same day IgE and EOS 
measurements (a proxy for “initiation of treatment” protocols), with the proportion of 
patients in the high EOS-containing distribution groups being markedly lower. 
Interestingly, the exclusion of EOS data measured within two or four weeks of an 
exacerbation appeared to have no impact on the distribution groups. The reasons for 
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the observed lack of extreme fluctuation in EOS around the time of an exacerbation 
are not clear when considering the observed inherent variability in blood eosinophils, 
expected in response to patient and pharmacological factors [13,14], and evidenced 
by the differences we observed in ‘same day’ and ‘maximum value’ results. It could 
be because similar fluctuations occurred with exacerbations managed at home (with 
use of higher doses of ICS/without the use of oral corticosteroids) or was possibly 
accounted for by fluctuations that occurred during sub-clinical exacerbations in which 
biomarker levels changed in the absence of changes in symptoms. Katz et al, in a 
population of severe asthmatics, whilst observing intra-patient eosinophil variability, 
reported that 85% of patients with a blood eosinophil count > 150 µ/L at screening, 
remained at or above this level in the following year [13]. They also found that blood 
eosinophils were a better predictor of treatment response to mepolizumab than 
sputum eosinophils, speculating that this may be associated with IL-5 mediated 
eosinophilic inflammation being the result of both local and systemic inflammation. 
Findings in the current study, suggest that maximum EOS in a year, regardless of 
exacerbation history, may be the most appropriate measure to identify patients 
suitable for targeted biologic therapy. Suruki et al, when describing the number of 
patients eligible for anti-IgE or anti-IL5 therapy in a severe population of asthmatics, 
used drug label criteria, potentially excluding some eligible patients from anti-IL5 
therapy where EOS assessment had been based on screening (‘same day’) 
measurements [15]. 
Median EOS levels in the studied population were higher (400µ/L) than that reported 
by Price et al (200µ/L) in an electronic database study of primary care patients using 
their most recently recorded eosinophil count [16]. In comparison, we selected a 
severe population of asthmatics who had undergone an IgE measurement, and who 
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were therefore more likely to be from a secondary care population, and used 
maximum IgE and EOS values for describing the population.  The cut-point for 
determining the high EOS group was 400µ/L and was primarily chosen for being the 
upper limit of the normal reference range in NHSGGC. Other studies evaluating the 
effects of anti-IL5 therapies have used cut-points of 300 µ/L [17,18] and 400µ/L [6] to 
determine high eosinophil status. In the context of clinical outcomes, patients with 
elevated blood eosinophils defined by 300µ/L [19] and 400 µ/L [16] cut-points have 
been reported as being at increased risk of frequent asthma exacerbations. Only a 
weak correlation between same day serum EOS and IgE was observed, at odds with 
the traditionally held view that these biomarkers are positively correlated [20], and 
suggests that more routine testing of IgE in severe asthma to identify patients with a 
treatable trait may be warranted. 
In terms of patterns of demographic characteristics, the high IgE groups were more 
often younger, male patients, who were less likely to have comorbid COPD; whilst 
patients from the high EOS groups tended to be treated with oral corticosteroids 
(BTS step 5), be associated with a greater incidence of osteoporosis, and have 
higher levels of systemic inflammation. None of the patterns were suggestive of 
previously described phenotypes of asthma based on cluster analyses – for 
example, we did not observe a group of older, obese female patients with late onset 
asthma in the low eosinophilic groups [21-23]. Although it should be noted that age of 
onset of asthma was not reliably recorded in the present database. 
With respect to asthma exacerbations, the low IgE/low EOS group was suggestive of 
a benign pattern despite them being highly treated i.e. consistent with a high 
symptom/low exacerbation profile group.  On the other hand, groups with high 
eosinophils were more prognostic of healthcare episodes, being particularly 
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associated with frequent severe exacerbations. In the UK electronic medical data 
record, primary care study, blood eosinophils >400µ/L were associated with frequent 
exacerbations of all severities, possibly reflecting the differences in populations 
studied [16]. Patients with high IgE/high EOS had the most frequent moderate 
exacerbations (courses of oral steroids). In addition, the high EOS/low IgE group 
appeared to be associated with an excessive number (>3) of ED attendances; 
however, no significant differences were observed in the frequencies of moderate or 
severe exacerbations in patients with high EOS (regardless of IgE status) vs. those 
with high IgE (regardless of EOS status).  Thus, EOS and IgE appear largely 
independent markers of asthma morbidity. 
A limitation of this analysis is that a selected population that had undergone IgE 
testing were evaluated, and therefore the findings are not generalizable to a general 
population of patients with severe asthma.  There are also some limitations to using 
electronic medical records for database evaluation, namely the reliance on complete 
and accurate recording of data, and items such as confirmation of diagnosis, 
incidence of comorbidities and patients’ use of prescribed therapy, not being easily 
verified. In addition, whilst every effort was made to identify the primary reason for 
attendances to emergency departments/hospital as asthma, incorrect or incomplete 
coding may have resulted in some anomalies. However, the NHSGGC uses a 
unique patient identifier which is tagged on 99% of health events, providing an 
extensive number of linked datasets resulting in a comprehensive, multi-source 
database from both primary and secondary care. 
In conclusion, this large database study identifies a considerable group of patients 
with severe asthma with low IgE /high EOS who are not currently suitable for  anti-
IgE therapy and who may benefit from an alternative. As EOS levels fluctuate over 
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time in response to patient and pharmacological features, we hypothesise that 
maximum EOS in a year, regardless of exacerbation history, may be the most 
appropriate measure to identify suitable patients. Interestingly, no significant 
correlation was observed between IgE and EOS, but our  data suggest that a low 
IgE/low EOS sub-phenotype appears more benign and high EOS groups are at 
increased risk of frequent, severe exacerbations.  
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Table 1: Characteristics of patients with severe asthma (BTS Step ≥4) 
Characteristic Severe asthma population  
(n=884) 
Male gender, % (n) 31.3 (277) 
Age (years), mean (SD) 54.7 (15.9) 
Height (m), mean (SD) 1.62 (0.09) 
Weight (kg), mean (SD) 79.1 (22.6) 
BMI (kg/m2), mean (SD) 30.0 (7.9) 
Smoking status, % (n): 
Current 
Ex 
Never 
Missing n 
 
24.7 (87) 
38.9 (137) 
36.4 (128) 
532 
BTS step, % (n): 
4 
5 
 
70.0 (619) 
30.0 (265) 
Maximum IgE in 2 years prior to index date, kU/L 
Median (min-max) 
Interquartile range 
 
86 (2-5000) 
22-289 
Maximum EOS in 2 years prior to index date, µ/L 
Median (min-max) 
Interquartile range 
 
400 (70-4200) 
200-700 
Comorbidities, % (n)  
COPD 32.5 (287) 
Cardiovascular disease 12.2 (108) 
Cerebrovascular disease 5.2 (46) 
Diabetes mellitus  13.9 (123) 
Osteoporosis 4.3 (38) 
Depression 5.7 (50) 
Bronchiectasis 7.6 (67) 
Interstitial lung disease 0 
Nasal polyposis 1.0 (9) 
Asthma exacerbations in 2 years prior to index date, % 
(n) 
≥1 asthma exacerbation1 
Number of A&E visits due to asthma 
0 
1 
≥2 
Number of hospitalisations due to asthma 
0 
1 
≥2 
 
 
55.0 (486) 
 
85.9 (759) 
8.9 (79) 
5.2 (46) 
 
46.5 (411) 
31.8 (281) 
21.7 (192)  
≥1 prescriptions in 2 years prior to index date, % (n) 
SABA 
LABA 
ICS 
ICS/LABA 
LTRA 
 
97.3 (861) 
60 (530) 
24.9 (220) 
96.4 (852) 
66.0 (583) 
1Exacerbation defined by the number of courses of oral corticosteroids ≥20mg/day.BMI: body mass 
index; BTS: British Thoracic Society; A&E: accident & emergency;SABA: short-acting beta2-agonist; 
LABA: long-acting beta2-agonist; ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist  
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Table 2: Distribution of patients with severe asthma (BTS Step ≥4) according to 
IgE/EOS level groups (N=852) 
 
 High IgE Low IgE Total 
High EOS 33.2 (283) 20.2 (172) 455 
Low EOS 19.0 (162) 27.6 (235) 397 
Total 445 407 852 
Data presented as % (n). 
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Table 3: Demographic and clinical characteristics according to IgE/EOS distribution groups in patients with severe 
asthma (BTS Step ≥4) 
Characteristic High EOS/ 
High IgE 
(n=283) 
 
High EOS/ 
Low IgE 
(n=172) 
 
Low EOS/ 
High IgE 
(n=162) 
 
Low EOS/ 
Low IgE 
(n=235) 
 
 
 
P-value 
Male gender, % (n) 34.6 (98) 28.5 (49) 36.4 (59) 24.7 (58) 0.031 
Age (years), mean (SD) 51.6 (16.2) 59.2 (16.2) 52.1 (15.4) 57.9 (14.0) <0.001 
Height (m), mean (SD) 1.65 (0.11) 1.61 (0.08) 1.63 (0.09) 1.61 (0.10) 0.045 
Weight (kg), mean (SD) 82.1 (21.6) 74.5 (22.5) 81.9 (22.0) 78.6 (24.3) 0.031 
BMI (kg/m2), mean (SD) 30.5 (8.2) 28.5 (8.0) 31.1 (7.7) 30.1 (7.8) 0.128 
Smoking status, % (n): 
Current 
Ex 
Never 
Missing n 
 
24.5 (23) 
40.4 (38) 
35.1 (33) 
189 
 
16.2 (12) 
45.9 (34) 
37.8 (28) 
98 
 
33.3 (19) 
36.8 (21) 
29.8 (17) 
105 
 
25.7 (29) 
36.3 (41) 
38.1 (43) 
122 
 
0.428 
BTS step: 
4 
5 
 
64.7 (183) 
35.3 (100) 
 
64.0 (110) 
36.0 (62) 
 
80.2 (130) 
19.8 (32) 
 
73.2 (172) 
26.8 (63) 
 
0.001 
Comorbidtities, % (n)  
COPD 25.1 (212) 37.2 (64) 25.69 (42) 42.1 (99) <0.001 
Cardiovascular disease 9.2 (26) 18.0 (31) 11.7 (19) 12.3 (29) 0.050 
Cerebrovascular disease 4.6 (13) 6.4 (11) 5.6 (9) 
 
4.7 (11) 0.829 
Diabetes mellitus  14.1 (40) 9.9 (17) 11.1 (18) 18.3 (43) 0.066 
Osteoporosis 3.9 (11) 7.6 (13) 0.6 (1) 5.5 (13) 0.016 
Depression 2.5 (7) 4.1 (7) 7.4 (12) 8.9 (21) 0.007 
Bronchiectasis 6.4 (18) 11.6 (20) 4.3 (7) 8.9 (21) 0.057 
Nasal polyposis 1.8 (5) 0.6 (1) 0 0.9 (2) 0.275 
Allergy* 38.2 (108) 30.8 (53) 38.9 (63) 32.8 (77) 0.251 
Biomarkers, median (interquartile range)  
C Reactive Protein (mg/l) 
Min, Max 
Missing n 
24.0 (6-88) 
1, 531 
19 
43 (8-205) 
0.9, 448 
13 
13.5 (4-75) 
1, 391 
20 
17.5 (6-65) 
1, 498 
15 
<0.001 
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Neutrophil count (109/l) 
Min, Max 
Missing n 
9.9 (7.0-14.1) 
2, 30.7 
0 
10.3 (7.2-14.9) 
2.9, 38.5 
0 
8.1 (6-11.1) 
2.1, 33.3 
0 
8.7 (5.5-12.4) 
2.1, 42.7 
0 
<0.001 
Lymphocyte count (109/l) 
Min, Max 
Missing n 
3 (2.3-3.9) 
1.1, 8.0 
0 
3 (2.2-3.9) 
1.3, 5.8 
0 
2.5 (2-3.3) 
0.8, 7.8 
0 
2.7 (1.9-3.4) 
0.6, 8.7 
0 
<0.001 
Platelet count (109/l) 
Min, Max 
Missing n 
344 (293-417) 
139, 947 
0 
358 (307-440) 
159, 1119 
0 
304 (254-381) 
61, 878 
0 
315 (265-385) 
102, 1202 
0 
<0.001 
BMI: body mass index; BTS: British Thoracic Society 
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Table 4: Summary of asthma exacerbations and asthma therapies in 2 years 
prior to index date according to IgE/EOS distribution groups in patients with 
severe asthma (BTS Step ≥4) 
Characteristic High EOS/ 
High IgE 
(n=283) 
High EOS/ 
Low IgE 
(n=172) 
Low EOS/ 
High IgE 
(n=162) 
Low EOS/ 
Low IgE 
(n=235) 
 
P-
value 
Number of exacerbations* of 
asthma, median (IQR) 
1 or more (% (n)) 
Min, Max 
 
1 (0-5) 
53.0 (150) 
0, 13 
 
0 (0-4) 
49.4 (85) 
0, 12 
 
1 (0-4) 
61.1 (99) 
0, 12 
 
1 (0-4) 
57.9 (136) 
0, 11 
 
0.695 
Frequent exacerbator** 76.0 (215) 60.5 (104) 67.9 (110) 60.4 (142) <0.001 
Number of hospital 
admissions for asthma, % (n) 
0 
1 
2 
3 
4 
5 or more 
Med (IQR) 
Min, Max 
 
 
35.3 (100) 
33.9 (96) 
13.1 (37) 
7.1 (20) 
5.3 (15) 
5.3 (15) 
1 (0-2) 
0, 14 
 
 
46.5 (80) 
32.6 (56) 
6.4 (11) 
4.1 (7) 
4.1 (8) 
5.8 (10) 
1 (0, 1) 
0, 17 
 
 
47.5 (77) 
32.7 (53) 
12.3 (20) 
2.5 (4) 
1.2 (2) 
3.7 (6) 
1 (0, 1) 
0, 13 
 
 
54.5 (128) 
30.2 (71) 
6.8 (16) 
3.4 (8) 
2.1 (5) 
2.9 (7) 
0 (0, 1) 
0, 13 
 
 
0.009 
Number of A&E attendances 
for asthma, % (n): 
0 
1 
2 
3 or more 
Med (IQR) 
Min, Max 
 
 
80.6 (228) 
12.7 (36) 
4.2 (12) 
2.5 (7) 
0 (0-0) 
0, 6 
 
 
86.0 (148) 
7.0 (12) 
2.3 (4) 
4.7 (8) 
0 (0-0) 
0, 9 
 
 
85.2 (138) 
11.1 (18) 
1.2 (2) 
2.5 (4) 
0 (0-0) 
0, 9 
 
 
91.1 (214) 
5.1 (12) 
1.7 (4) 
2.1 (5) 
0 (0-0) 
0, 4 
 
 
0.044 
≥1 prescriptions in 2 years 
prior to index date, % (n) 
SABA 
LABA 
ICS 
ICS/LABA 
LTRA 
 
 
99.3 (281) 
58.7 (166) 
26.9 (76) 
97.5 (276) 
72.8 (206) 
 
 
97.1 (167) 
59.3 (102) 
29.7 (51) 
92.4 (159) 
63.4 (109) 
 
 
98.1 (159) 
63.0 (102) 
29.6 (48) 
96.9 (157) 
67.3 (109) 
 
 
94.9 (223) 
60.9 (143) 
25.1 (59) 
97.0 (228) 
58.7 (13.8) 
 
 
0.025 
0.662 
0.648 
0.219 
0.480 
*Exacerbation defined by the number of courses of oral corticosteroids ≥20mg/day;**Frequent 
exacerbator defined as those with ≥2 Rx for prednisolone ≥20mg DDD in the year prior to index date 
OR ≥ 1 hospital admission for asthma in the year prior to the index date. IQR: interquartile range; 
A&E: accident & emergency; SABA: short-acting beta2-agonist; LABA: long-acting beta2-agonist; ICS: 
inhaled corticosteroid; LTRA:  
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Figures legend 
Figure 1: Flow of patients 
ABPA: allergic bronchopulmonary aspergillosis 
§Read code or ICD code for asthma, and in the 2 years prior to index date: aged ≥ 18 
years, ≥ one prescription for any of: SABA, ICS, ICS/LABA, ≥ 1 estimation of IgE 
¥Three patients appeared in both categories 
Figure 2: Comparison of IgE/EOS distribution groups in patients with severe 
asthma, using different measurement criteria 
Figure 3: Scatterplot and correlation coefficient of same day EOS versus same day 
IgE for BTS step 4 and above 
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Figure 1: Flow of patients 
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Figure 2: Comparison of IgE/EOS distribution groups in patients with severe 
asthma, using different measurement criteria 
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Figure 3: Scatterplot and rank correlation coefficient of same day EOS (µ/L) 
versus same day IgE (kU/L) for BTS step 4 and above 
 
 
Rank correlation coefficient = 0.276, p<0.001 (N=578) 
